GBI Research's latest report, ""Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets"" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.
Payers continue to play an important role in market access. Products are increasingly being rejected for reimbursement, adversely affecting the market share of these products.
HEOR plays a critical part in market access
HTA has gained importance in reimbursement decisions
Pricing and reimbursement are the key elements of market access
Reasons to buy
This report will allow you to -
Table of Content
Health Economic and Outcomes Research (HEOR)
A Systemic Value Development Plan for HEOR
Types of Economic Evaluations
Overview of Cost-Effectiveness Analysis
Quality-Adjusted Life Year in HEOR
Pharmacoeconomic Modelling Methods
Health Technology Assessment (HTA) in Market Access
Key Benefits of HTA
Process and Dimensions of HTA
Principle HTA Regulatory Agencies
Risk Sharing Agreements When Limited Evidence is Available for HTA
Pricing and Reimbursement
Factors Affecting Pricing Decision
Pricing of a New Drug
Pharmaceutical Pricing Policies in the US
Impact Of Affordable Care Act on Market Access
Pharmaceutical Pricing and Reimbursement Policies in Canada
Pharmaceutical Pricing and Reimbursement Policies in Europe (UK, Germany, France, Italy and Spain)
Parallel Trade in Europe
Pharmaceutical Pricing and Reimbursement Policies in Japan
Economic Analysis Alongside Clinical Trials
Harmonization of Drug Approval and Marketing for Effective Market Access
Key Challenges for Achieving Optimum Market Access
Make an enquiry before buying this Report
Please fill the enquiry form below.
Orthomyxoviridae infections are caused by a large family of viruses spanning six genera. They are responsible for the occurrence of influenza amongst both humans and animals. Influenzavirus A, Influenzavirus B, Influenzavirus C, Isavirus, Thogotovirus and Quaranjavirus are the six different types of orthomyxoviridae. Each of these genera also include several serotypes or sub-types, Influenza A includes major sub-types such as H1N1, H1N2, H2N2, ...
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease. The cause of rheumatoid arthritis is not known. The joint inflammation of rheumatoid arthritis causes swelling, pain, stiffness and redness in the joints. It can lead to a significant loss of mobility due to pain and joint destruction. The disease is also systematic, i.e. it affect extra articular tissues throughout the body. The disease is three times more common in women as...
Cytokines refer to diverse non-antibody proteins that act as molecular messengers between the cells. Also, other terms are in use to describe specific type of cytokines. For instance, monokines are the cytokines that are produced by mononuclear phagocytic cells, interleukins are the cytokines that act as molecular messengers between leukocytes and lymphokines are the cytokines that are produced by activated lymphocytes. Cytokines are identifi...